David J. Andorsky, MD, board-certified medical oncologist and hematologist at Rocky Mountain Cancer Centers, discussed findings from a study on patterns of Bruton tyrosine kinase (BTK) inhibitor care use and social determinants of health (SDOH) among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
David J. Andorsky, MD, board-certified medical oncologist and hematologist at Rocky Mountain Cancer Centers, a practice in the US Oncology Network, discussed findings from a study on patterns of care and social determinants of health (SDOH) among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The research was presented at the 2023 American Society of Hematology Annual Meeting.
Transcript
Your study found that rural settings were associated with different treatment patterns for CLL/SLL. Can you briefly discuss those trends and their implications?
What we observed was that the patients in a rural environment were actually a little more likely to receive one of the newer medications, either acalabrutinib or zanubritunib. It was not a huge effect size, and the number of patients in a rural environment were small in the study, so I would take those findings with sort of a note of caution or that it's more hypothesis-generating as opposed to definitive. It was reassuring, though, because I think one might have expected that you would see patients not getting those new medications in what's traditionally thought of as a kind of medically underserved environment. It's nice to see that those patients, in our network at least, have access to the latest medications.
As novel therapies are tested in clinical trials and approved, what can be done to try and close treatment gaps fueled by SDOH?
Understanding what patients' barriers are to receiving treatment. Is it a financial barrier? Is it that they don't have a ride to get to their office visits? That can be a big burden for people—I think less so with the oral medications because you don't have to come to clinic every week, but that still can be a barrier. Also, just medical literacy, patients not understanding why they need to take a treatment [or whether it is] really necessary. Those are all things that I think we can all keep working to address.
This transcript has been lightly edited for clarity.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More